Patient Self-administration of Cortisol for Cortisol-responding Disorders in Men and Women Over the Age of 17
Status:
Completed
Trial end date:
2016-12-31
Target enrollment:
Participant gender:
Summary
Participants diagnosed as having fibromyalgia, osteoarthritis, and rheumatoid arthritis are
to be brought to a minimum symptom state using a 3-week period during which they are to
ingest modest doses of cortisol tablets with weekly lowered tapered doses. Thereafter, the
participants are to be taught to self-administer cortisol tablets on the as-needed basis to
maintain the minimum symptom state. For this, they are to ingest a smaller-dosage, 5-day
tapered regimen of cortisol tablets to quench each reoccurring exacerbation of the disease at
its earliest stage. Participants are limited to using less than the safe use limit of
cortisol per month and are required to include a minimum of 10 days per month during which no
cortisol was ingested.